311PDLeuprorelin (LEUP) combined with Letrozole (LET) with/without everolimus (EVE) in ovarian suppressed premenopausal women with hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC): Primary analysis of LEO Trial (NCT02344550)

ConclusionsAdding EVE to LET demonstrated numerically improved PFS (D 4.3  Mo, median PFS), higher ORR. Significant improved PFS was noted in patients with visceral metastases.Clinical trial identificationNCT02344550.Legal entity responsible for the studySung-Bae Kim.FundingNovartis, Dongkook Pharma Co. Ltd.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

Publication date: Available online 24 May 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Kasey Halsey, Jing Wu, Chang Su, Ben Hsieh, Thomas Yi, Scott A. Collins, Benjamin Kimia, Paul J. Zhang, Terrance Healey, Zishu Zhang, Harrison X. Bai
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
Publication date: Available online 24 May 2020Source: European Journal of RadiologyAuthor(s): Lisa Loi, Ferdinand Zimmermann, Steffen Goerke, Andreas Korzowski, Jan-Eric Meissner, Katerina Deike-Hofmann, Anne Stieber, Peter Bachert, Mark Edward Ladd, Heinz-Peter Schlemmer, Sebastian Bickelhaupt, Sarah Schott, Daniel Paech
Source: European Journal of Radiology - Category: Radiology Source Type: research
ConclusionThe proposed multiparametric MRI-based SLICs+MTh method performs noninvasive assessment of NACT response in osteosarcoma that may improve cancer treatment monitoring, planning, and overall prognosis.Key Points• The simple linear iterative clustering supervoxels and Otsu multithresholding-based technique (SLICs+MTh) successfully estimates the proportion of necrosis, viable tumor, and edema in osteosarcoma in the course of chemotherapy.• The proposed technique is noninvasive and uses multiparametric MRI to measure necrosis as an indication of anticancer treatment response.• SLICs+MTh-based necrosis w...
Source: European Radiology - Category: Radiology Source Type: research
Publication date: Available online 24 May 2020Source: Pathology - Research and PracticeAuthor(s): Tania Franceschini, Elisa Capizzi, Francesco Massari, Riccardo Schiavina, Michelangelo Fiorentino, Francesca Giunchi
Source: Pathology Research and Practice - Category: Pathology Source Type: research
Psychologists say anxiety and uncertainty prompt irrational decisions — like turning down a transplant when an organ becomes available.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Transplants Emergency Medical Treatment Coronavirus (2019-nCoV) Liver Fear (Emotion) Anxiety and Stress Cancer Heart your-feed-science your-feed-healthcare Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Qingzhi Guo, Li Li, Qimei Bo, Li Chen, Li Sun, Hongtang Shi
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
ConclusionsCombination treatment with everolimus, letrozole and trastuzumab is well tolerated and active in ER+, HER2+ and/or mutant solid tumors, including breast and cervical cancer. Clinical benefit (PR/SD≥6 months) was seen in 7 of 9 patients (78%), including patients with HER2 mutations in the absence of overexpression and/or amplification and patients with no genomic alterations in the PI3K/AKT/mTOR pathway. Enrollment is ongoing.Citation Format: Janku F, Hong DS, Atkins JT, Karp DD, Tsimberidou AM, Piha-Paul SA, Subbiah V, Naing A, Fu S, Moulder SL, Tripathy D, Meric-Bernstam F, Wheler JJ. Everolimus, letrozole a...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusion Prostate cancer is common in the UK, so news of new treatment options is always welcome. However, this study does not show for certain that olaparib works better than no treatment, even for men with the DNA repair mutations identified in the study as responding to treatment. The first problem is the lack of a comparison group. We can see what happened to the men who took the drug, but not what might have happened if they had not taken it, or if they'd taken another type of treatment not already tried. And most of the men treated did not get any benefit from the drug. Only 16 of the 49 men assessed showed any s...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Medication Older people Source Type: news
Conclusion: Although a potential signal of benefit from MM-121 was observed in the HR+ group, the same was not observed in the TN group, and overall the results are inconclusive. Biomarker analyses, including pharmacodynamics studies, are ongoing. The observed safety profile is consistent with the expected toxicities associated with ErbB inhibitors and weekly paclitaxel, and did not impact exposure or compliance on treatment. Citation Format: Frankie A Holmes, Kristi J McIntyre, Ian E Krop, Cynthia R Osborne, John W Smith II, Manuel R Modiano, Manish Gupta, Leona B Downey, Rita Nanda, Mansoor N Saleh, Jonathan R Young, Ker...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Anemia | Biology | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Endocrine Therapy | HER2 | Hormones | Legislation | Liver | Ovarian Cancer | Ovaries | Pharmaceuticals | Study | Tamoxifen | Toxicology | Urology & Nephrology | Women